Login
  • Bookmark
  • PDF
  • Share
  • CaseIQ
 

Commissioner Of Central Excise, Mumbai-V v. Servo-Med Ind. Pvt. Ltd.

CESTAT
Jun 18, 2004
Smart Summary (Beta)

Factual and Procedural Background

The appeal arises from a dispute concerning whether the process of “sterilization” performed on fully manufactured disposable syringes and needles amounts to manufacture under the Central Excise Act, 1944. The appellants undertake sterilization of products cleared under the brand name “BEHRING,” belonging to a third-party manufacturer. The lower authority had held that sterilization was an essential and incidental process amounting to manufacture, attracting excise duty and denying Modvat credit. The Commissioner of Central Excise (Appeals) (CCE(A)) had set aside this finding, holding that sterilization does not amount to manufacture as it does not create a new or distinct product. The Revenue has appealed against the CCE(A)’s order.

Legal Issues Presented

  1. Whether the process of sterilization on fully manufactured syringes and needles amounts to “manufacture” under Section 2(f) of the Central Excise Act, 1944.
  2. Whether the sterilization process results in a new or distinct product that attracts excise duty under the same tariff heading.
  3. Whether the appellants are entitled to Modvat credit on inputs used in the sterilization process.

Arguments of the Parties

Appellant's Arguments

  • The appellants argued that sterilization is a process incidental or ancillary to manufacture under Section 2(f) of the Central Excise Act, 1944.
  • They contended that sterilization enhances the value and commercial identity of the product, making it fit for human medical use, thereby amounting to manufacture.
  • The appellants relied on various Supreme Court and Tribunal decisions to establish that the process results in a new commodity with a distinct brand and use.
  • They claimed entitlement to Modvat credit as the duty liability was upheld.

Respondent's Arguments

  • The respondents contended that sterilization does not change the basic structure of the product and only affects its quality (sterile vs. non-sterile), thus it does not amount to manufacture.
  • They argued that Section 2(f) does not include “integral or inextricable” processes and that imposing such a view would amount to judicial addition to the statute.
  • The respondents relied on the absence of chapter notes or section notes in the Central Excise Tariff Act, 1985, to exclude sterilization from manufacture.

Table of Precedents Cited

Precedent Rule or Principle Cited For Application by the Court
State of Tamil Nadu v. Pyare Lal Malhotra (Supreme Court) Levy of Central Excise duty on processed goods under the same tariff heading. Relied upon by the lower authority and the court to support the levy of duty on sterilized syringes and needles.
Laminated Packings (Supreme Court) Permissibility of excise levy on duty-paid goods when a new commodity emerges under the same tariff heading. Relied upon by the court to conclude that sterilization results in a new commercial identity and use, attracting excise duty.
Kapri International (Supreme Court) Recognition of manufacture when a distinct product emerges. Used by the court to affirm that sterilization changes the character and use of the product, constituting manufacture.
Shri Krishna Keshav Laboratories Ltd. (Tribunal) Clarification on processes amounting to manufacture and duty liability. Supported the court’s view that sterilization is a manufacturing process attracting excise duty.
Kiran Spinning (Supreme Court) Definition of manufacture and change in use or substance. The court distinguished this precedent, finding it not applicable as sterilization causes a change in use and substance.
Vivek Re-rolling Mills (Tribunal) Eligibility for Modvat credit where duty liability is established. Relied upon to allow the appellants the benefit of Modvat credit subject to documentary proof.

Court's Reasoning and Analysis

The court analyzed whether sterilization constitutes manufacture under Section 2(f) of the Central Excise Act, 1944. It noted that sterilization kills germs without altering the basic structure of syringes and needles, but enhances the product’s value and makes it fit for human medical use, thereby changing its commercial identity and use. The court rejected the CCE(A)’s finding that sterilization does not amount to manufacture, observing that the absence of chapter or section notes in the Central Excise Tariff Act, 1985, is not determinative.

The court referred to authoritative decisions establishing that a new commodity with distinct commercial identity and use emerging from a process can attract excise duty even under the same tariff heading. It found that sterilization meets this criterion as the product post-sterilization is commercially distinct and usable, unlike the pre-sterilized product.

The court also noted that the CCE(A)’s order was perfunctory and failed to adequately apply the relevant legal principles. While upholding the duty liability, the court found merit in the appellants’ claim for Modvat credit and remanded the issue to the original authority for verification of documentary evidence supporting the credit claims.

Holding and Implications

The court ALLOWED THE APPEAL and set aside the CCE(A)’s order. It held that the process of sterilization on syringes and needles amounts to manufacture under Section 2(f) of the Central Excise Act, 1944, attracting excise duty. The finding establishes that a process which changes the commercial identity and use of a product, even without altering its basic structure, can be treated as manufacture.

The court also directed that the claim for Modvat credit be examined afresh by the original authority upon production of relevant documents. No new precedent was created beyond affirming established principles regarding manufacture and excise duty liability in the context of sterilization processes.

Show all summary ...

[Order per : S.S. Sekhon, Member (T)]. - Revenue is in appeal against the order of CCE(A), who has found & ordered -

“3.............There is no dispute that the appellants undertake the process of “sterilization” on fully manufactured products i.e. “Syrings & needles” which are disposable. There is no dispute that the product were cleared under the brand name “BEHRING” belonging to a third person/ manufacturer. The vital issue which needs determination is as to -
I have gone through the case records and have considered the views of both the sides. There is no dispute that the appellants undertake the process of “sterilization” on fully manufactured products i.e. ‘Syrings and needles’ which are disposable. There is no dispute that the products were cleared under the brand name “BEHRING” belonging to a third person manufacturer. The vital issue which needs determination is as to whether the process of sterilization would amount to manufacture whether any new, distinct product would emerge during the process of sterilization. It is very important to understand as to what is the process of sterilization. The process of sterilization kills germs as is well-known. The applied process, in no way, brings any change in basic structure of syringe and needles, although after sterilization the value of the product gets enhanced. Therefore, I am not inclined to accept that there some kind of transformation taken place. The words ‘sterile’ and ‘non-sterile’ merely state the quality of the manufactured product. The Section 2(f) of the C.Ex. Act, 1944 defines and includes the process which is incidental and ancillary process. There is no mention of “integral or inextricable” process in Section 2(f) and to super impose these terms referred by the Asstt. Commr. would amount adding to something new in the written code. I find that there are catena of decisions which support the view points of the appellants. Further, there do not appear any definition in the relevant chapter notes or section notes of Central Excise Tariff Act, 1985 which brings the process of ‘sterilization’ under the ambit of manufacture of Section 2(f) of the C. Ex. Act, 1944.”

2. The lower authority had found -

(i)         “(d)….......as regards the essentiality or necessity” of the process of sterilization before sales of the disputed product. I find no dispute........” and continues thereafter to find the process employed to be essential for the manufacture before the product could be marketed and that the process was essential and incidental is covered under Rule 2(f) of the rules, to be amounting to manufacture.
(ii)       Thereafter relying upon State of Tamil Nadu v. Pyare Lal Malhotra [ (S.C.) and Laminated Packings, he held that duty of Central Excise could be levied and recovered under the same tariff in this case.
(iii)      It was also held that substantial value addition has taken place the use of another person Brand name would not entitle the benefit of Notification 1/93.
(iv)      He denied the claim of Modvat credit.

3. Heard both sides and considered the issue and it is found -

(a)        The fact of ‘new commodity’ known to the people dealing with the same in commerce to have emerged by the employment of the process undertaken to in eligible manufacture result is now a well settled proposition. The Apex Court has held that to arrive at a conclusion to attract again a levy on duty paid goods, under the same tariff heading is permissible. Reliance is well placed by Ld. DR on the case of Laminated Packings [ (S.C.)] and Kapri International [ (S.C.)] and Shri Krishna Keshav Laboratories Ltd. [ (Tri.)]. The reliance of the ld. Advocate on the case of Kiran Spinning [ (S.C.)] especially para 4 will thereof, not help the case of the respondents, since ‘some charge in use substance’ has been achieved in the case before us. An article with distinct Brand name and separate end use/quality has emerged by the activity undertaken. The use/character of a ‘syringe’ which was brought and which emerged has charged. While the goods brought were not fit for use on Humans Medical Needles as made not usable till sterilized. The commercial identity nature use and understanding has changed, manufacturing has taken place, excise levy is attracted.
(b)        The CCE (A)’s order is perfunctory, it does not deal, how the law applied by the lower authority is not applicable. The finding of absence of chapter notes need not be a reason to uphold the CCE (A)’s order. The same is set aside.
(c)        We find however merits in the plea of the ld. Advocate of the Respondents for benefit of credit since duty liability to duty is being upheld. The issue is no longer Res Integra. Reliance of the ld. Advocate on the case of Vivek Re-rolling Mills [ (Tri.)] to allow eligibility of Modvat credit claim is well founded and is to be granted. However in absence of documents of duty payment, the issue is to be remitted back to the original authority to examine the documents for the Modvat credit claims, which will be presented by the Respondents and grant the same on quantum as eligible.

4. Appeal allowed as remand in above terms.